Novartis drug does not show survival benefit in liver cancer

ZURICH (Reuters) - Swiss drugmaker Novartis said on Wednesday its drug Afinitor did not show a survival benefit in patients with advanced liver cancer. Data from a late-stage trial found that Afinitor did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or intolerance to another drug sorafinib. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/novartis-drug-does-not-show-survival-benefit-liver-053222291.html